Drug Profile

Research programme: TEAD protein degradation therapeutics - Amphista Therapeutics

Alternative Names: TEAD Targeted Glue™ program - Amphista Therapeutics

Latest Information Update: 05 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amphista Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action TEA domain transcription factor degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

24 Apr 2026 Research programme: TEAD protein degradation therapeutics - Amphista Therapeutics is available for licensing as of 24 Apr 2026. 9465246
24 Apr 2026 Pharmacodynamics data from a preclinical trial in Cancer released by Amphista Therapeutics
24 Apr 2026 Amphista Therapeutics anticipates candidate selection completion for TEAD programme in the second half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com